- with iodine-131-labelled antibody to carcinoembryonic
- antigen: phase I/II study with comparative biodistributionAdams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D. and Weiner, L. M., 1998, Increased
- of intact and F(ab‚)2 antibodies. British Journal of Cancer,
- 70, 521-525.aæ nity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Research, 58, 485-490.Lenhard, R. E., Order, S. E., Spunberg, J. J., Asbell, S. O.
- and Leibel, S. A., 1985, Isotopic immunoglobulin: a newBardies, M. and Chatal, J.-F., 1994, Absorbed doses for internal radiotherapy from 22 beta-emitting radionuc-
- systemic therapy for advanced Hodgkin‚s disease. Journal
- of Clinical Oncology, 3, 1296- 1300.lides: beta dosimetry of small spheres. Physics in Medicine and Biology, 39, 961-981.Lote, C. J., 1992, Principles of Renal Physiology (London: Chapman
- and Hall).Barendsen, G. W., 1982, Dose-fractionation, dose-rate and iso-eåectrelationshipsfornormaltissue-responses.Muthaswamy, M. S., Roberson, P. L. and Buchsbaum, D. J.,
- 1998, A mouse bone marrow dosimetry model. Journal ofInternational Journal of Radiation Oncology Biology and Physics, 8, 1981-1997.
- Nuclear Medicine, 39, 1243-1247.
- O‚Donoghue, J. A., 1994, The impact of tumor cell proliferationBegent, R. H. J., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D.,
- in radioimmunotherapy. Cancer, 73 (suppl.), 974-980.
- Pedley, R. B., Boden, J. A., Boden, R., Begent, R. H. J.,Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J. W. and Robson, L., 1996, ClinicalTurner, A., Haines, A. M. R. and King, D. J., 1994,
- The potential for enhanced tumour localisation by poly(-evidence of eæ cient tumor targeting based on single-chain Fv antibody selected from a combinatorial library.
- ethylene glycol) modi? cation of anti-CEA antibody. British
- Journal of Cancer,70, 1126- 1130.Nature Medicine, 2, 979-984. Casey, J. L., King, D. J., Chaplin, L. C. et al. 1996, Preparation,
- Pedley, R. B., Boden, J. A., Boden, R., Boxer, G. M., Flynn,
- A. A., Keep, P. A. and Begent, R. H. J., 1996, Ablationcharacterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab‚ fragments. British
- of colorectal xenografts with combined radioimmunother-
- apy and tumor blood ? ow-modifying agents. CancerJournal of Cancer, 74, 1397-1405. Casey, J. L., Pedley, R. B., King, D. J., Green, A. J.,
- Research, 56, 3293- 3300.
- Pedley, R. B., Boden, J. A., Dale, R. and Begent, R. H. J.,Yarranton, G. T. and Begent, R. H. J., 1999, Dosimetric evaluation and radioimmunotherapy of anti-1993, Comparative radioimmunotherapy using intact or
- F(ab‚)2 fragments of131I anti-CEA antibody in a colonictumour multivalent Fab‚ fragments. British Journal of Cancer, 81, 972-980.
- xenograft model. British Journal of Cancer, 68, 69-73.
- Press, O. W. Eary, J. F., Appelbaum, F. R. et al. 1995, PhaseChapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S. and King, D. J., 1999, Therapeutic antibody fragments
- II trial of I-131 B1 (anti-CD20) antibody therapy with
- autologous stem-cell transplantation for relapsed B-cellwith prolonged in vivo half-lives. Nature Biotechnology, 17, 780-783.
- lymphomas. Lancet, 346, 336-340.
- Press, W. H., Teukolsky, S. A., Vetterli ng, W. T. andChester, K. A., Begent, R. H. J., Robson, L., Keep, P., Pedley, R. B., Boden, J. A., Boxer, G., Green, A.,
- Flannery, B. P., 1992, Numerical Recipes in C (Cambridge:
- Cambridge University Press).Winter, G., Cochet, O., Hawkins, R. E., 1994, Phage libraries for generation of clinically useful antibodies.Read, D. A., Cooper, M. S., Boden, R., Boden, J. A., Chester,
- K. A., Begent, R. H. J., 1997,99mTc labelling of MFE-23Lancet, 343, 455-456. Dale, R. G., 1996, Dose-rate eåects in targeted radiotherapy.
- (an anti-CEA single chain antibody) [abstract]. British
- Journal of Cancer, 75 (suppl. 1), 34.Physics in Medicine and Biology, 41, 1871-1884.Schultes, B. C., Zhang, C. S., Xue, L. Y., Noujaim, A. A. and
- repair capacity and repair kinetics deduced from multif-
- ractionated or continuous irradiation regimens withMadiyalakan, R., 1999, Immunotherapy of human
- incomplete repair. British Journal of Cancer, 49, 263-269.ovarian carcinoma with OVARIXTM Mab-B43.13 in a
- Thomas, G. D., Chappell, M. J., Dykes, P. W. et al. 1989,human-PBL-SCID/BG mouse model. Hybridoma, 18,
- Eåect of dose, molecular size, aæ nity, and protein binding 47-55.
- on tumor uptake of antibody or ligand: a biomathematical Sharda, N., Yang, C.-R, Linsella, T. and Boothman, D.,
- model. Cancer Research, 49, 3290- 3296. 1997, Radiation resistance. In J. R. Bertino (ed.),
- Tom, B. H., Rutzky, L. P., Jakstys, M. M., Oyasu, R., Kaye, EncyclopediaofCancer(London:AcademicPress),
- C. I. and Kahan B. D., 1976, Human colonic adenocarci-pp. 1409 -1419.
- noma cells. In Vitro, 12, 180-191. Sitzmann, J. V., Order, S. E., Klein, J. L, Leichner, P. K.,
- Travis, E. L. and Tucker, S. L., 1987, Iso-eåect models and Fishman, E. K. and Smith, G. W., 1987, Conversion by
- fractionated radiation therapy. International Journal of new treatment modalities of nonresectable to resectable
- Radiation Oncology Biology and Physics, 13, 283-287. hepatocellular cancer. Journal of Clinical Oncology, 5,
- Wong, J. Y. C., Williams, L. E., Demidecki, A. J., Wessels, 1566-1573.
- B. W. and Yan, X. W., 1991, Radiobiologic studies Strand, S.-E, Zanzonico, P. and Johnson, T. K., 1993,
- comparing yttrium-90 irradiation and external beam irra-Pharmacokinetic modeling. Medical Physics, 20, 515-527.
- diation in vitro. International Journal of Radiation Oncology
- Biology and Physics, 20, 715-722.Thames, H. D., Withers, H. R. and Peters, L. J., 1984, Tissue
International Journal of Radiation Biology
Volume 77, 2001 - Issue 4